# Neoadjuvant Sintilimab in Combination With Carboplatin and Nab-paclitaxel in Untreated Salivary Gland Malignant Neoplasms

> **NCT05000892** · PHASE2 · RECRUITING · sponsor: **Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University** · enrollment: 15 (estimated)

## Conditions studied

- Salivary Gland Malignant Neoplasms
- Salivary Gland Tumors

## Interventions

- **DRUG:** Sintilimab , Carboplatin, Nab-paclitaxel

## Key facts

- **NCT ID:** NCT05000892
- **Lead sponsor:** Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-12-10
- **Primary completion:** 2023-06-01
- **Final completion:** 2027-10-01
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2022-12-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05000892

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05000892, "Neoadjuvant Sintilimab in Combination With Carboplatin and Nab-paclitaxel in Untreated Salivary Gland Malignant Neoplasms". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05000892. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*